Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antibody-conjugated doxorubicin liposomal - NanoSmart/NanoValent

Drug Profile

Antibody-conjugated doxorubicin liposomal - NanoSmart/NanoValent

Alternative Names: ANA-conjugated doxorubicin liposomal - NanoSmart/NanoValent; Anti-nuclear antibody-conjugated doxorubicin liposomal - NanoSmart/NanoValent; Doxorubicin liposomal - NanoSmart/NanoValent

Latest Information Update: 28 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NanoSmart Pharmaceuticals; NanoValent Pharmaceuticals
  • Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Immunoconjugates; Small molecules
  • Mechanism of Action CD antigen inhibitors; DNA intercalators; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ewing's sarcoma
  • New Molecular Entity No

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Ewing's sarcoma; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 28 Dec 2019 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA
  • 28 Dec 2019 No recent reports of development identified for preclinical development in Ewing's Sarcoma in USA
  • 28 Dec 2019 No recent reports of development identified for preclinical development in Precursor-cell-lymphoblastic-leukaemia-lymphoma in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top